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bstract
A nanoparticle insulin delivery system was prepared by complexation of dextran sulfate and chitosan in aqueous solution. Parameters of the
ormulation such as the final mass of polysaccharides, the mass ratio of the two polysaccharides, pH of polysaccharides solution, and insulin
heorical loading were identified as the modulating factors of nanoparticle physical properties. Particles with a mean diameter of 500 nm and a zeta
otential of approximately −15 mV were produced under optimal conditions of DS:chitosan mass ratio of 1.5:1 at pH 4.8. Nanoparticles showed
pherical shape, uniform size and good shelf-life stability. Polysaccharides complexation was confirmed by differential scanning calorimetry and
ourier transformed infra-red spectroscopy. An association efficiency of 85% was obtained. Insulin release at pH below 5.2 was almost prevented upo 24 h and at pH 6.8 the release was characterized by a controlled profile. This suggests that release of insulin is ruled by a dissociation mechanism
nd DS/chitosan nanoparticles are pH-sensitive delivery systems. Furthermore, the released insulin entirely maintained its immunogenic bioactivity
valuated by ELISA, confirming that this new formulation shows promising properties towards the development of an oral delivery system for
nsulin.
2006 Elsevier B.V. All rights reserved.
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. Introduction
Colloidal carriers made under mild conditions by complexa-
ion of oppositely charged natural polymers, also known as
olyelectrolytes, represent a promising vehicle to protect pro-
eins against harsh gastrointestinal conditions and to control
he release rate of proteins [1–3]. Also, natural polysaccha-
ides have demanded particular interest due to their attractive
iocompatible, biodegradable, hydrophilic and protecting pro-
erties, which have demonstrated favourable characteristics for
rug entrapment and delivery [4]. However, due to the labile
hysicochemical properties of proteins, gentle nanoencapsula-
ion conditions must be provided to assure the maintenance of
heir structural bioactivity. Particular attention has been given
o protein-loaded chitosan-based nanoparticles [5–7]. Chitosan,
∗ Corresponding author. Tel.: +351 222078949; fax: +351 222003977.
E-mail address: bruno.sarmento@ff.up.pt (B. Sarmento).
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n unbranched polyamine of d-glucosamine and N-acetyl glu-
osamine molecules, is characterized for its biodegradable,
on-toxic and biocompatible properties [8] providing several
iomedical, pharmaceutical and food applications. Moreover,
hitosan has the significant potential of reducing transepithelial
lectrical resistance and transiently opening tight conjunction
etween epithelial cells [9]. In addition, its mucoadhesive prop-
rty [10] is another advantage for promoting drug adsorption
ue to combination with anionic substructures such as sialic
cid moieties of the mucosa layer. The adhesion of chitosan
t the site of drug absorption offers various advantages for an
mproved uptake of therapeutic peptides [11,12].
Additional coincorporation of highly charged density polyan-
ons onto chitosan nanoparticles can improve nanoparticle prop-
rties concerning protein association efficiency and modulation
f drug release [13,14]. It has been previously noted that the
tronger the protein–polyions complex is the slower will be the
ate of protein release due to enhance of electrostatic interactions
15].
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Taking into account these considerations, dextran sulfate
DS), a biodegradable and biocompatible branched negatively
harged polyion with approximately 2.3 sulfate groups per glu-
osyl residue, was selected to formulate DS/chitosan nanoparti-
les. Chitosan and DS have been formulated as polyelectrolyte
omplex gels with swelling characteristics [16] and controlled
elease properties [17] and have been extensively used as multi-
ayer films for cell culture [18]. Additionally, they are intrin-
ically hydrophilic, which contributes for longer circulation
imes in vivo and allows the encapsulation of water-soluble
roteins.
In the present work insulin was chosen as the model protein.
t is a well known 51 amino acids protein, produced nowadays by
NA recombination techniques and used subcutaneously in the
reatment of diabetes mellitus. Although several attempts have
een developed regarding alternative routes of insulin adminis-
ration [19–21], the oral approach remains the most attractive
ue to convenience and high patient compliance. However, the
ioavailability of insulin after oral administration is normally
ow, due to its low stability in the gastrointestinal tract (GI),
ow partition coefficient and the physical barrier of the intestinal
pithelium. One approach to improve the gastrointestinal uptake
f low molecular weight proteins is to bind them to colloidal sys-
ems like nanoparticles, protecting them from degradation in the
astrointestinal tract and promoting the transport into systemic
irculation [22,23].
Since the size of nanoparticles and protein stability are essen-
ial for an efficient pharmacologic effect of insulin, the main
bjective of this paper was to establish a nanoparticulate sys-
em produced by polyelectrolyte complexation between DS and
hitosan, and evaluate their potential as insulin carriers. The
hysical and morphological properties of nanoparticles were
nvestigated in accordance with formulation parameters and the
elease profile of insulin was also determined regarding its poten-
ial for oral delivery.
. Materials and methods
.1. Materials
Low molecular weight (MW) chitosan (≈50 kDa) and low
W dextran sulfate (8 kDa) were purchased from Sigma (Por-
ugal). High MW dextran sulfate (500 kDa) was obtained from
KC® (Denmark). Dextran sulfate stock solutions were pre-
ared in deionized water (Milli-Q®) by overnight magnetic
tirring and chitosan solutions were prepared by dissolution
f chitosan in deionized water containing 1% (v/v) acetic acid
ollowed by filtration through a paper filter Millipore #2 and
tored at 4 ◦C. Human zinc-insulin crystal (Lot RS0325, 7.0 mg
yophilized human biosynthetic insulin per vial) was a gift from
illy Portugal.
.2. Preparation of nanoparticlesNanoparticle complexation between DS and chitosan was
erformed employing aqueous solutions of oppositely charged
olymers in a final volume of 120 mL. Unless otherwise men-
2
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ioned, complexes were obtained after dropwise addition of
hitosan solution at pH 5.0 to DS solution at pH 3.2 under
agnetic stirring followed by additional mixing for 15 min at
00 rpm to final concentrations of 0.15% DS and 0.10% chi-
osan (DS/chitosan mass ratio 1.5:1). For insulin association,
mg of the protein was previously dissolved in the DS solution
efore chitosan complexation. These conditions were obtained
fter preliminary studies that provided the best results taking
nto account the desired mean particle size and insulin associa-
ion efficiency.
.3. Nanoparticle characterization
Measurements of particle size were performed by photon
orrelation spectroscopy (PCS) at 25 ◦C with a detection angle
f 90◦ and zeta potential by laser Doppler anemometry (LDA)
sing a Malvern Zetasizer and Particle Analyzer 5000 (Malvern
nstruments) (n≥ 6).
.4. Stability of nanoparticles
The stability of nanoparticles was determined monitorizing
heir mean particle size and zeta potential over time. After pro-
uction, nanoparticles were stored at 4 ◦C in aqueous solution
nd then the size and zeta potential were measured after 0, 7,
4, 28, 42 and 60 days of shelf-life.
.5. Isolation of particles
Nanoparticles were collected by centrifugation at 14,000 rpm
20,000 × g) for 45 min. Supernatant were used for insulin deter-
ination. Nanoparticles were kept at 4 ◦C for further experi-
ents.
.6. Insulin association efficiency
The amount of insulin associated with the particles was calcu-
ated by the difference between the total amount used to prepare
he particles and the amount of insulin present in the aqueous
hase after centrifugation. The association efficiency (AE) was
etermined indirectly applying the following equation:
E = total amount of insulin−free insulin in supernatant
total amount of insulin
×100
.7. In vitro release studies
Nanoparticles were placed into 20 mL of USP XXVI buffers,
amely hydrochloric acid pH 1.2, acetate pH 4.5, acetate pH 5.2
nd phosphate pH 6.8 and incubated at 37 ◦C under magnetic
tirring. At pre-determined time intervals, samples were taken
or insulin determination and replaced by fresh medium..8. Insulin determination
Insulin concentration was determined spectrophotometri-
ally using the Coomassie PlusTM Bradford Assay (Pierce,
faces
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TB. Sarmento et al. / Colloids and Sur
ockford, USA) modified Bradford assay [24]. Briefly, insulin
amples and Bradford reagent were mixed at 1:1 (v/v) ratio in
96-well plate and incubated at room temperature for 15 min.
he absorbance was measured at 595 nm on a thermomax plate
eader (PowerWaveX; Bio-Tek, Winooski, VT, USA). Calibra-
ion curves were made using supernatant of unloaded particles
or AE and unloaded nanoparticles for in vitro release profile.
ll the results were made in triplicate.
.9. Scanning (SEM) and transmission (TEM) electronic
icroscopy
For the SEM analysis, nanoparticles were mounted on metal
tubs using adhesive tape, gold coated under vacuum and exam-
ned on a JEOL JSM-840 SEM (Japan). For TEM, one drop
f sample was placed in a grid, treated with uranil acetate and
bserved in a Zeiss EM 902A TEM.
.10. Differential Scanning calorimetry (DSC)
Thermograms were obtained using a Shimadzu DSC-50
ystem (Shimadzu, Kyoto, Japan). Samples were lyophilized,
rimped in a standard aluminium pan and heated from 20 to
50 ◦C at a rate of 10 ◦C/min under constant purging of nitrogen
t 20 ml/min.
.11. Fourier transform infra-red (FTIR) analysis
IR-spectra were measured using a Bomem IR-spectrometer
Bomem, Canada). Samples were lyophilized, gently mixed with
00 mg of micronized KBr powder and compressed into discs at
force of 10 kN for 2 min using a manual tablet presser (Perkin
lmer, Norwalk, USA). For each spectrum a 256-scan interfero-
ram was collected with a 4 cm−1 resolution in the mid-IR region
t room temperature. Insulin spectra were obtained according to
double subtraction procedure [25] and insulin-free systems
nd water vapor spectra were collected under identical condi-
ions for blank subtraction. All samples were run in triplicate
nd the data shows the average of the three measurements.
.12. Immunological bioactivity of insulinThe integrity of the insulin released from nanoparticles was
ssessed by a reported HPLC method [26] while its bioactivity
as assayed by an ELISA test (Mercodia, Uppsala, Sweden).
liquots of samples taken during release assays were accu-
T
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able 1
nfluence of polyelectrolytes concentration on nanoparticle properties
S (%) Chitosan (%) z-Average number (n
.05 0.05 479 ± 118*
.10 0.10 665 ± 210
.15 0.15 846 ± 100
.20 0.20 1012 ± 187*
he ratio between chitosan and DS was kept at 1/1 (w/w).
* The mean difference is significant at the 0.05 level.B: Biointerfaces 53 (2006) 193–202 195
ately diluted with deionized water (Milli-Q®) regarding the
deal concentration range of the method (1–200 mU/l) using the
anufacture’s protocol and its relative bioactivity was calcu-
ated by comparison with values obtained by Bradford analysis
f the same aliquots.
.13. Statistical analysis
The t-test and the one-way analysis of variance (ANOVA)
ith the pairwise multiple comparison procedures (Student–
ewman–Keuls method) were performed to compare two or
ultiple groups, respectively. All analyses were run using the
PSS program (Version 14.0, SPSS Inc., USA) and differences
ere considered to be significant at a level of P < 0.05.
. Results and discussion
Complex coacervation between chitosan and DS is a mild
rocess and was used to prepare nanoparticles at ambient tem-
erature without using sonication or organic solvents. Resulting
S/chitosan nanoparticle colloidal suspension presented a deep
nd typical Tyndall effect. Thus, it is a suitable procedure to
ncapsulate sensitive materials such as proteins, which are sen-
itive to different stress factors [27]. Being insulin an ampho-
eric molecule it is able to be electrostatically attached to such
anoparticles composed of DS and chitosan with a high avidity,
llowing its association with the stable colloidal drug carrier.
he insulin monomer contains many ionizable groups due to
amino acid residues capable of attaining a positive charged
olyelectrolyte like chitosan and 10 amino acid residues capa-
le of attaching a negative charged polyelectrolyte like DS [28].
hese properties might be highly responsible for the entrapment
f insulin into DS/chitosan nanoparticles.
Factors affecting the characteristics of DS/chitosan nanopar-
icles and the optimal conditions for their preparation were
tudied.
Primary assays were done in order to establish the range of
olyelectrolytes concentration to produce nanoparticles with an
ppropriate submicron size and a significant value of insulin
E. Therefore, concentrations range from 0.05% to 0.20% for
oth chitosan and DS were used to prepare nanoparticles in the
roportion of 1:1, at final pH of 4.8. Results are depicted in
able 1.
As expected, increasing the polyelectrolytes concentration
ed to an increase of nanoparticles mean size in a linear depen-
ency.
m) AE (%) Zeta potential (mV)
54.7 ± 4.8* 0.2 ± 0.1
71.5 ± 2.9* −0.4 ± 0.1
87.4 ± 2.7* 1.2 ± 0.3
96.4 ± 4.3* 3.2 ± 0.4
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Table 2
Influence of DS:chitosan mass ratio on nanoparticle properties
DS (%) Chitosan (%) DS:chitosan mass ratio z-Average number (nm) AE (%) Zeta potential (mV)
0.05 0.10 1:2 1612 ± 248* 48.6 ± 7.7* 2.4 ± 0.1*
0.10 0.10 1:1 665 ± 210 71.5 ± 2.9* −0.4 ± 0.1*
0.15 0.10 1.5:1 489 ± 11 85.4 ± 0.5 −14.2 ± 0.5*
0.20 0.10 2:1 598 ± 25 87.2 ± 0.9 −16.7 ± 0.9*
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* The mean difference is significant at the 0.05 level.
Zeta potential was near zero for all formulations, which indi-
ates that the balance between positive and negative charges is
imilar, as expected from positive and negative mass of both
olyelectrolytes.
The AE of insulin was also directly related to the polyelec-
rolytes concentration. This trend is in agreement with the mech-
nism of protein association to polyelectrolyte nanoparticles
ediated by ionic interactions. The presence of higher concen-
rations of polyelectrolytes probably shifts the ionic equilibrium
etween insulin and polyelectrolytes towards the associated
omplexes. Similar conclusion was also drawn from insulin-
oaded chitosan/TPP nanoparticles [29].
Considering the desired nanoscale size and insulin AE, 0.10%
hitosan concentration was chosen for further experiments.
hen, attempts to find the best DS:chitosan mass ratio were
one according stoichiometries shown in Table 2.
Nanoparticles formulated with a DS:chitosan mass ratio of
:2 showed a higher mean particle size than obtained with a
olysaccharides ratio of 1:1, 1.5:1, 2:1 and 2.5:1 (P < 0.05), but
o significant differences were found between these last three
ass ratios. The finding that the ideal DS:chitosan mass ratio is
igher than 1:1 indicates that DS is possibly a colloidal protector
reventing particle aggregation and simultaneously a robustness
actor of nanoparticles strength. In fact, only chitosan shows
elling properties. DS does not swells in aqueous environment,
robably inducing a squeeze effect on the nanoparticle matrix
y increasing the final DS:chitosan mass ratio.
Zeta potential of the systems was dependent on the poly-
lectrolytes ratio. The zeta potential was almost zero for a
S:chitosan mass ratio of 1:1, but decreased to −14.2 mV when
ore negative charged DS was added (1.5:1) and even more
−16.7) when that ratio reached 2:1. Thus, one can deduce that
he excess of DS is placed mainly on the surface of the nanopar-
icle, which may interact with positively charged insulin and
herefore increase of insulin AE.
The obtained values for insulin AE showed a DS:chitosan
ass ratio dependency. The increase in DS/chitosan ratio from
:2 to 1.5:1 allowed the entrapment of more insulin although
t
v
n
able 3
nfluence of curing time on nanoparticle properties
S (%) Chitosan (%) Time of curing (min) z-A
.15 0.10 5 452
.15 0.10 15 489
.15 0.10 30 543
* The mean difference is significant at the 0.05 level.9 ± 39 90.6 ± 1.2 −21.5 ± 1.6*
igher mass ratio than 1.5:1 did not originate any variation on
nsulin AE (P > 0.05). It can be postulated that the affinity of
nsulin to sulfate groups of DS is higher than for amine groups
f chitosan due the stronger electrostatic interaction between
ositively charged protein and negative sulfate groups. Thus,
he DS:chitosan mass ratio of 1.5:1 appeared to be adequate
o entrap a higher amount of insulin. Nanoparticles formulated
ith a DS:chitosan mass ratio of 1.5:1 (0.15% DS and 0.1%
hitosan) was then selected to analyze the effect of additional
uring on nanoparticles properties. In order to assess this param-
ter, nanoparticles were produced and additionally stirred for 5,
5 and 30 min. The obtained results are summarized in Table 3.
The effect of nanoparticles curing time did not show any sta-
istical differences on the nanoparticles mean size (P > 0.05),
hich suggests a fast complexation between polyelectrolytes
nd a stabilization effect during additional stirring. The decrease
f zeta potential with the curing time can be explained by the sur-
ace attachment of additional negative DS molecules in excess
n the surrounding aqueous medium, which is accompanied by
slight increase of particle mean size. Furthermore, insulin AE
as independent on additional curing time since obtained results
or different curing times were statistically similar (P > 0.05).
ne can assume that insulin interaction with polyelectrolytes
appens very fast remaining the protein entrapped within the
anoparticles.
Then, nanoparticles were produced with a different MW DS.
anoparticles produced with both 8 and 500 kDa MW DS orig-
nated practically the same mean particle size around 490 nm
nd zeta potential around −15 mV, but the decrease of DS MW
rom 500 to 8 kDa originated a small decrease of insulin AE
rom 85.4 to 81.4% (P < 0.05). Apparently, a longer polyanion
hain has the capacity to bind proteins in a stronger complex
15]. DS is probably the major responsible for the association of
nsulin to nanoparticles and therefore its MW can be important
o determine the degree of association to insulin.
The effect of theorical insulin loading was investigated by
arying the final polymer:insulin mass ratio to produce different
anoparticles and the results are depicted in Table 4.
verage number (nm) AE (%) Zeta potential (mV)
± 45 84.3 ± 1.5 −9.3 ± 0.3*
± 11 85.4 ± 0.5 −14.2 ± 0.5*
± 76 85.2 ± 2.0 −17.0 ± 0.3*
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Table 4
Influence of polymer:insulin mass ratio on nanoparticle properties
DS (%) Chitosan (%) Theorical insulin (%) z-Average number (nm) AE (%) Zeta potential (mV)
0.15 0.10 0 493 ± 86 – −16.4 ± 2.6
0.15 0.10 0.0012 504 ± 53 86.7 ± 1.9 −18.9 ± 0.5
0.15 0.10 0.0035 527 ± 44 84.2 ± 0.8 −15.7 ± 0.1
0.15 0.10 0.007 489 ± 11 85.4 ± 0.5 −14.2 ± 0.5
0.15 0.10 0.01 603 ± 26 87.3 ± 1.9 −10.5 ± 0.1*
* The mean difference is significant at the 0.05 level.
Table 5
Influence of pH of chitosan solution on nanoparticle properties
DS pH Chitosan pH Final pH z-Average number (nm) AE (%) Zeta potential (mV)
3.25 5.0 4.8 489 ± 11 85.4 ± 0.5* −14.2 ± 0.5
3.25 4.0 3.9 505 ± 8 90.8 ± 1.3 −8.9 ± 0.5*
3 ± 19 *
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50 and 110 ◦C and an exothermic peak at 222.5 ◦C, an inter-
mediated value of the endothermic peaks obtained for isolated
polyelectrolytes. Isolated polymers were characterized by the
presence of initial endothermic peaks at 62.0 and 60.6 ◦C for
Table 6
Influence of storing time on mean diameter and zeta potential of nanoparticle’s
produced with a DS:chitosan mass ratio of 1.5:1
Time (days) z-Number (nm) Zeta potential (mV)
0 538 ± 22 −14.2 ± 0.5
7 534 ± 21 −11.1 ± 0.9
14 589 ± 58 −12.1 ± 1.1.25 3.0 3.2 522
* The mean difference is significant at the 0.05 level.
Mean particle size was found to be statistically independent
n the theorical insulin loading as well as the insulin AE. In
he range of initial insulin concentration studied, the theori-
al insulin loading capacity varied from 0.5% to 3.8% (w/w).
hese values are relative low to expect a significant effect of
nsulin concentration on the final nanoparticle properties, as
bserved. Therefore, the capacity of saturation of nanoparticles
ith insulin seems not to be reached in this insulin concentration
ange and, consequently, the ionic nature of insulin association
o nanoparticles is highlighted here. Zeta potential of nanoparti-
les slightly decreased with increasing theorical insulin loading,
learly indicating that a significant fraction of the protein is
ttached to the surface of the nanoparticles.
Because of the acidic properties of DS (pKa < 1), it probably
hows negative sulfate groups in a wild range of pH. Chitosan as
n ionizable polymer contains different properties according the
H environment where it is dissolved. Consequently, nanopar-
icles properties are probably dependent on the pH of aqueous
olution where they are produced. To assess this hypothesis, dif-
erent nanoparticles where formulated, varying the final pH of
olloidal system by using chitosan dropping solutions at differ-
nt pH (Table 5).
The variation of the final pH of nanoparticles production
etween 4.8 and 3.2 did not significantly influence their mean
article size. However, it decreased the value of zeta potential,
robably because the degree of ionization of DS shifts towards
ts protonated form. Insulin AE increased with the decrease of
he final pH from 4.8 to 3.2 mostly because insulin must be
ighly protonated at lower pH and, probably, the alteration of
onizable state of the protein promotes its interaction with sulfate
roups of DS.
The stability of nanoparticles was determined by the varia-
ion of their mean particle size and zeta potential with the time.
fter production, nanoparticles were stored at 4 ◦C in aqueous
nvironment and at pre-determined times, size an zeta potential
ere measured as described before. Table 6 shows the values
ound.
2
4
693.0 ± 1.5 −5.7 ± 0.1
The results did not show significant differences on nanopar-
icles mean size and zeta potential up to 28 days of storage. An
ncreasing effect was observed on size and zeta potential, after
8 and 42 days, respectively. This effect may be attributed to
ome aggregation of nanoparticles.
The morphology of DS/chitosan nanoparticles is depicted in
igs. 1 and 2. SEM micrograph of DS/chitosan nanoparticles
Fig. 1) shows clustered spherical-like particles, with smooth
urfaces. Nevertheless, they were easily resuspended in aqueous
olution. Also, they showed a broad uniform size, in agreement
ith photon spectroscopy analysis (Table 2).
TEM images revealed well-defined spherical nanoparticles.
nner dark color is probably due to a deposition of the stain sug-
esting a relatively high density of nanoparticles matrix. Also,
t is visible the superficial deposition of DS on the nanoparti-
les produced with an excess of DS on the final formulation,
hich confirms the hypothesis that DS is a colloidal protector
reventing particle aggregation.
The thermograms of DS/chitosan nanoparticles and isolated
olyelectrolytes are depicted in Figs. 3–5. The DS/chitosan
anoparticles exhibited a DSC broad endothermic peak between8 623 ± 72 −9.3 ± 1.1*
2 678 ± 15* −9.0 ± 3.6*
0 754 ± 20* −3.2 ± 1.9*
* The mean difference is significant at the 0.05 level.
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Fig. 1. SEM micrographs of DS/chitosan nanoparticles produced with a
DS:chitosan mass ratio of 1.5:1 at pH 4.8.
Fig. 2. TEM micrographs of DS/chitosan nanoparticles produced with a
DS:chitosan mass ratio and of 1.5:1 (A) and 2:1 (B), both systems at pH 4.8.
Fig. 3. Thermograms of (a) chitosan at pH 5.0, (b) dextran sulfate at pH 3.25
and (c) DS/chitosan nanoparticles produced with a DS:chitosan mass ratio of
1.5:1at final pH of 4.8.
Fig. 4. Thermograms of DS/chitosan nanoparticles produced with a DS:chitosan
mass ratio of (a) 1:1, (b) 1.5:1, (c) 2:1 and (d) 2.5:1.
Fig. 5. Thermograms of (a) insulin, (b) empty DS/chitosan nanoparticles and
(c) insulin-loaded DS/chitosan nanoparticles produced with a DS:chitosan mass
ratio of 1.5:1 at pH of 4.8.
faces B: Biointerfaces 53 (2006) 193–202 199
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DS/chitosan nanoparticles were also done through FTIR analy-
sis. Fig. 7 depicts FTIR spectra of insulin, empty DS/Chitosan
and insulin-loaded DS/chitosan nanoparticles.B. Sarmento et al. / Colloids and Sur
hitosan and DS, respectively, and higher exothermic peaks at
11.0 and 210.5 ◦C, respectively (Fig. 3). Endothermic peaks
ave been correlated with evaporation of water associated to
ydrophilic groups of polymers while exothermic peaks have
een related to degradation of polyelectrolytes due to dehydra-
ion, depolymerization and pyrolitic reactions [30,31].
The exothermic peak of DS/chitosan nanoparticle is inter-
reted as the cleavage of electrostatic interactions between both
olyelectrolytes. Similar electrostatic interactions have been
eferred to explain chitosan/DS interactions [17,32]. Additional
xothermic behaviour was observed for temperatures higher
han 325 ◦C, which is probably evidence of polymer decompo-
ition. When comparing the temperature of water evaporation
n isolated polymers and nanoparticles, one can found that it
ccurred later on nanoparticle thermogram. Probably, a tiny
mount of water remained associated in the nanoparticle matrix
o hydrophilic residues of polymers and required higher tem-
erature to be completely removed. This hypothesis strongly
upports the assumption of the formation of a high nanoparticle
atrix density.
Analyzing the effect of DS:chitosan mass ratio on the ther-
ograms of different nanoparticles (Fig. 4), it is noted that by
ncreasing this ratio, the value of the exothermic peak, firstly
ttributed to the cleavage of electrostatic interactions between
oth polyelectrolytes decreases, approaching to the exothermic
eak of isolated DS (210.5 ◦C). This can be assumed that the
ontribution of DS mass to the overall nanoparticles mass is as
igher as the initial DS:chitosan mass ratio. Thus, the higher is
he overall DS mass, the lower is the relative number of negative
harge groups that contribute to the electrostatic interaction with
ositive chitosan, decreasing the amount of energy required for
he cleavage of electrostatic interactions It can also be confirmed
y the lower value of the exothermic peak observed for higher
S:chitosan mass ratio nanoparticles.
The thermogram of pure insulin shows two endothermic
eaks at 62.3 and 83.0 ◦C and a tiny and broad exothermic peak
t 251.1 ◦C (Fig. 5). The two endothermic peaks attributed to
enaturation process and water loss [33] continued appearing on
he insulin-loaded nanoparticles, indicating not only that it was
uccessfully entrapped but also that no significant damage might
ave occurred in insulin structure. First endothermic peak seems
o be a contribution of insulin, chitosan and DS and the sec-
nd, of minor intensity, a transition associated with the protein.
he exothermic peak registered at 229.3 ◦C appeared shifted to
igher exothermic temperature than DS/chitosan nanoparticles,
hich can be understood by an interaction between nanopar-
icle components and a slight increase of resistance to thermic
egradation. This resistance is probably the result of a new ionic
hemical interaction between opposite group charges.
In order to confirm DS/chitosan interactions, isolated poly-
lectrolytes and nanoparticles were analyzed by FTIR spec-
roscopy. Fig. 6 shows spectra of DS, chitosan and DS/chitosan
anoparticles.The FTIR spectrum of chitosan shows a peak of amide
ond at 1636 cm−1 due to C O stretching and C–N stretch-
ng vibration, a strong protonated amino peak at 1573 cm−1
rom N–H bending and at 1411 cm−1 from N–H stretching
F
l
1ig. 6. FTIR spectra of (a) dextran sulfate at pH 3.25, (b) chitosan at pH 5.0 and
c) DS/chitosan nanoparticles produced with a DS:chitosan mass ratio of 1.5:1
t pH 4.8.
ecause it is obtained from partial N-deacetylation of chitin.
n addition, the peak absorbance of amino groups of chitosan
t 1153 cm−1 (N–H blending vibration) was also present as
ell as the peak around 1020 cm−1 originated by the symmetric
tretch of C–O–C. DS presented sulfyl peaks near 1026 cm−1
symmetric SOO− stretching vibration) and 1261 cm−1 (asym-
etric SOO− stretching vibration) as well as a band around
20 cm−1 corresponding to S–O–S vibrations. Chitosan peak at
411 cm−1 and DS peak at 1261 cm−1 can be used to moni-
orize the formation of nanoparticles since they are exclusive
f both polymers. FTIR spectrum of DS/chitosan nanoparti-
les revealed small changes in the amine and sulfate absorption
ands at 1568 and 1024 cm−1, but peaks at 1413 and 1259 cm−1
ere consistent with the presence of electrostatic interactions,
learly indicated the presence of both polyelectrolytes in the
nal nanoparticle composition.
Attempts to investigate the entrapment of insulin intoig. 7. FTIR spectra of (a) insulin, (b) DS/chitosan nanoparticles and (c) insulin-
oaded DS/chitosan nanoparticles produced with a DS:chitosan mass ratio of
.5:1 at pH 4.8.
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Fig. 8. Insulin cumulative release profile from insulin-loaded DS/chitosan
nanoparticles produced with DS:chitosan mass ratio of 1.5:1 at final pH of 4.8.
Nanoparticles were submitted to curing time of 15 min and the theorical insulin
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Fig. 9. Insulin cumulative release profile at pH 1.2 (A) and 6.8 (B) from insulin-
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Most of the time, the pharmaceutical properties of therapeu-
tic proteins closely depends on the retention of their biological
activity. Consequently, the pharmaceutical efficacy should be
assessed by monitoring the biological activity of protein at theoading was 2.3% (final insulin 0.006%). Release assay was performed at pH 1.2
), 4.5 (©), 5.2 () and 6.8 () (vertical bars represent standard derivations
ased on three replicates).
Insulin spectrum reveals two peaks on the nanoparticle
bsorption bands in the Amide I (∼1650 cm−1) and Amide
I (∼1540 cm−1) mainly due C O stretching vibration, which
s characteristic of protein spectrum. These two peaks are
lso present in the insulin-free DS/chitosan nanoparticle spec-
rum. Therefore, after insulin entrapment, nanoparticle spectrum
resents a very similar aspect compared with insulin-unloaded
anoparticles. However, an increase of the peak intensity at
562 cm−1 and mainly at 1640 cm−1 can be understood as the
resence on insulin.
Insulin release behaviour from DS/chitosan nanoparticle was
valuated at different aqueous pH buffers. The results are plotted
n Fig. 8.
No insulin released from nanoparticles placed at pH of 1.2
nd 4.5 and 5.2, was detected whilst at pH 6.8 insulin release
resented a sustained release profile with 40% of insulin being
eleased within the first 15 min following a lower release rate.
fter 300 min of the assay time, the amount of insulin released
t pH 1.2 and 4.5 was insignificant and at pH 5.2, less than
% of insulin was liberated. At pH lower than pI of insulin
5.3) [28], insulin presents an overall positive charge that is
ble to deeply interact with the polyanionic charge of nanopar-
icles provided by DS. At this pH range, the strong electrostatic
nteractions between insulin and DS may contribute to retain
nsulin in the DS/chitosan network. Additionally, DS/chitosan
anoparticles appear to preserve their physical integrity which
lso contributes to minimize insulin release by nanoparticle ero-
ion. After 300 min of assay at pH 6.8, 70% of insulin was
eleased and reached 73% after 24 h (Fig. 9). The initial stage of
nsulin release at pH 6.8 is attributed to the insulin located at the
urface of the nanoparticles and the remainder of the unreleased
nsulin is most probably entrapped within the nanoparticles.
hese results lead to assume that the in vitro release behaviour
f insulin from DS/chitosan nanoparticles was according to a
issociation mechanism and DS/chitosan nanoparticles are pH-
ensitive delivery systems.Fig. 9 represents the cumulative release profile of insulin
rom different DS/chitosan nanoparticles produced at differ-
nt pH environment. It can be observed that the release rate
as dependent on the pH of nanoparticle formation. Insulin
F
D
1
boaded DS/chitosan nanoparticles prepared at pH 4.8 (close symbols) and 3.2
open symbols) (vertical bars represent standard derivations based on three repli-
ates).
elease from nanoparticles produced at pH 3.2, with a higher
nsulin AE value, was faster than nanoparticles produced at pH
.8. Nanoparticles prepared at higher pH may have produced
tronger insulin–polyelectrolytes interactions, even though it
ight have occurred in a lower degree.
The effect of DS:chitosan mass ratio on the insulin cumulative
elease at pH 6.8 was then studied. As outlined in Fig. 10, the
ncrease of DS:chitosan mass ratio from 1:1 to 2:1 decreased
he insulin cumulative release. After a 24 h-assay insulin release
rom nanoparticles prepared with DS:chitosan mass ratio of 1:1,
.5:1 and 2:1 was 76%, 73% and 59%, respectively. This finding
uggested once more the main role of DS on insulin entrapment
s well on the sustained effect of insulin release.ig. 10. Insulin cumulative release profile at pH 6.8 from insulin-loaded
S/chitosan nanoparticles produced with different a DS:chitosan mass ratio of
:1 (©), 1.5:1 () and 2.0:1.0 () (vertical bars represent standard derivations
ased on three replicates).
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Fig. 11. The ELISA relative bioactivity of insulin released at pH 6.8 from
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255–267.S/chitosan nanoparticles produced with a DS:chitosan mass ratio of 1.5:1
black bars) and 2.1 (white bars) (results represent mean and standard devia-
ion based on three replicates).
nd of the formulation process [34]. To determine the relative
mmunogenic bioactivity of insulin, a specific solid phase two-
ite enzyme-linked immunosorbent assay (ELISA) was applied.
lectrostatic as well as hydrophobic interactions play a role in
he interaction between paratope of antibody and epitope of
nsulin and, thus, it is assumed that protein epitopes are to some
xtent conformation dependent [35]. Upon coating of ELISA
late with insulin, the possible loss of epitopes could be a con-
equence of insulin structural change. As shown in Fig. 11, the
nsulin released from nanoparticles in simulated intestinal pH
ithout enzymes kept entirely its bioactivity for at least 24 h.
hese results seem to indicate that the insulin did not suffer any
egradation process, namely hydrolyses or fibrillation instead
aintained its active form.
Results obtained in preliminary HPLC assays showed a
nique and well-defined peak on the chromatogram and no
ydrolysis degradation products of insulin were detected (results
ot shown). Thus, insulin retained its primary structure after
xposure to the intestinal 6.8 pH up to 24 h. The same conclusion
as obtained when analyzing the residual insulin chromatogram
eleased at pH 1.2, 4.5 and 5.2 where a single peak was detected
results not shown).
Regarding the insulin fibrillation process, the formation of
nsulin fibres from human insulin at simulated intestinal pH with
lag time of 49.4 h has been reported [36]. Also, at the concen-
ration range of 0.05 mg/ml, the same obtained in the present
ork, insulin was described predominately in a dimer/hexamer
orm which is a factor of fibrillation delay [37]. Consequently,
t is reasonable to assume that insulin molecules did not suffer
brillation neither during nanoparticles production nor during
he release time up to 24 h.
. ConclusionDS/chitosan nanoparticles produced by a mild coacerva-
ion method are suggested as a valid alternative to encapsulate
nsulin. Nanoparticles formulated by dropwise addition of a chi-
osan solution at pH 5 into a DS/insulin solution at pH 3.2
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ccording to a DS:chitosan mass ratio of 1.5:1, followed by
5 min of curing time, were selected as the optimized formula-
ion. Their morphology was assessed by electronic microscopy,
onfirming obtained granulometric analysis performed by pho-
on correlation spectroscopy. The interaction between polyelec-
rolytes and insulin was successfully confirmed by DSC and
TIR. Release studies established the ability of these nanopar-
icles to retain insulin at simulated gastric medium and pH
uffers of 4.5 and 5.2 values and a sustained release profile up
o 24 h at simulated intestinal medium. Quantification of insulin
eleased from nanoparticles by ELISA showed the preservation
f its immunogenic bioactivity, which supports the application of
hese nanoparticles as oral delivery systems for insulin. Present
nvestigations are being performed regarding the assessment of
nsulin in vivo oral bioactivity.
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